Alba Carreras

Alba Carreras

Auto-generated profile, based on publicly available information

Alba Carreras

Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Sahlgrenska University Hospital, University of Gothenburg, Sweden (A.C., K.R.B., M.H., F.B.).

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
VNVanasa Nageswaran
Vanasa Nageswaran
ACAlba Carreras
Alba Carreras
LRLeander Reinshagen
Leander Reinshagen
KBKatharina Beck
Katharina Beck
JSJakob Steinfeldt
Jakob Steinfeldt
AHArash Haghikia
Arash Haghikia
BACKGROUND: The microbially produced amino acid–derived metabolite imidazole propionate (ImP) contributes to the pathogenesis of type 2 diabetes. However, the effects of ImP on endothelial cell (EC) physiology and its role in atherosclerotic coronary artery disease are unknown. Using both human and animal model studies, we investigated the potential contributory role of ImP in the development of atherosclerosis. METHODS: Plasma levels of ImP were measured in patients undergoing elective cardiac angiography (n=831) by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Odds ratios and corresponding 95% confidence intervals for coronary artery disease were calculated based on the ImP quartiles using both univariable and multivariable logistic regression models. The effects of ImP on functional properties of ECs were assessed using HAECs (human aortic endothelial cells). In a mouse model of carotid artery injury, the impact of ImP on vascular regeneration was examined. Additionally, atheroprone Apoe −/− mice fed a high-fat diet were treated with and without ImP (800 µg), and aortic atherosclerotic lesion area was evaluated after 12 weeks. Next-generation sequencing, Western blot analysis, small interfering RNA–based gene knockdown, and tamoxifen-inducible Cre-loxP experiments were performed to investigate ImP-mediated molecular mechanisms. RESULTS: Plasma ImP levels in subjects undergoing cardiac evaluation were associated with increased risk of prevalent coronary artery disease. We found that ImP dose dependently impaired migratory and angiogenic properties of human ECs and promoted an increased inflammatory response. Long-term exposure to ImP compromised the repair potential of the endothelium after an arterial insult. In atheroprone Apoe −/− (apolipoprotein E −/− ) mice, ImP increased atherosclerotic lesion size. Mechanistically, ImP attenuated insulin receptor signaling by suppressing the PI3K (phosphoinositide 3-kinase)/AKT pathway leading to sustained activation of the FOXO1 (forkhead box protein O1) transcription factor. Genetic inactivation of endothelial FOXO1 signaling in ImP-treated mice enhanced the angiogenic activity and preserved the vascular repair capacity of ECs after carotid injury. CONCLUSIONS: Our findings reveal a hitherto unknown role of the microbially produced histidine-derived metabolite ImP in endothelial dysfunction and atherosclerosis, suggesting that ImP metabolism is a potential therapeutic target in atherosclerotic cardiovascular disease.

6 July 2010 in Respiratory Research
Verified
Journal Article
Open access
PDF file
ACAlba Carreras
Alba Carreras
MLMauricio Rojas López
Mauricio Rojas López
TTTheodora Tsapikouni
Theodora Tsapikouni
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat
DNDaniel Navajas
Daniel Navajas
RFRamon Farre
Ramon Farre
The aim was to test the hypothesis that the blood serum of rats subjected to recurrent airway obstructions mimicking obstructive sleep apnea (OSA) induces early activation of bone marrow-derived mesenchymal stem cells (MSC) and enhancement of endothelial wound healing.

1 July 2010 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
ACAlba Carreras
Alba Carreras
IAIsaac Almendros
Isaac Almendros
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat
DNDaniel Navajas
Daniel Navajas
RFRamon Farre
Ramon Farre

1 January 2012 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
IAIsaac Almendros
Isaac Almendros
ACAlba Carreras
Alba Carreras
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat
David GozalDavid Gozal
David Gozal
DNDaniel Navajas
Daniel Navajas
RFRamon Farre
Ramon Farre
Adult stem cells are undifferentiated cells that can be mobilized from the bone marrow or other organs, home into injured tissues, and differentiate into different cell phenotypes to serve in a repairing capacity. Furthermore, these cells can respond to inflammation and oxidative stress by exhibiting immunomodulatory properties. The protective and reparative roles of mesenchymal stem cells (MSCs), very small embryonic-like stem cells (VSELs), and endothelial progenitor cells (EPCs) have primarily been examined and characterized in auto-immune and cardiovascular diseases. Obstructive sleep apnea (OSA) is a very prevalent disease (4–5% of adult population and 2–3% of children) characterized by an abnormal increase in upper airway collapsibility. Recurrent airway obstructions elicit arterial oxygen desaturations, increased inspiratory efforts, and sleep fragmentation, which have been associated with important long-term neurocognitive, metabolic, and cardiovascular consequences. Since inflammation, oxidative stress and endothelial dysfunction are key factors in the development of the morbid consequences of OSA, bone marrow-derived stem cells could be important modulators of the morbid phenotype by affording a protective role. This mini-review is focused on the recent data available on EPCs, VSELs, and MSCs in both animal models and patients with OSA.